Download PDF
1 / Pages

Other users also viewed these articles

Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis Alejandro Balsa; Petra Díaz del Campo Fontecha; Lucía Silva Fernández; José Valencia Martín; Virginia Nistal Martínez; Fernando León Vázquez; M. Vanesa Hernández Hernández; Héctor Corominas; Rafael Cáliz Cáliz; José María Aguado García; Gloria Candelas Rodríguez; Nora Ibargoyen Roteta; Arturo Martí Carvajal; M. Nieves Plana Farras; Janet Puñal Riobóo; Hye Sang Park; Yolanda Triñanes Pego; Virginia Villaverde García;
Reumatol Clin. 2023;19:533-48
Practical aspects of biological throught levels and antidrug antibodies in rheumatoid arthritis and spondyloarthritis José Rosas; María Martín-López; Teresa Otón; Alejandro Balsa; Jaime Calvo-Alén; Raimon Sanmartí; Jesús Tornero; Loreto Carmona;
Reumatol Clin. 2020;16P2:378-85
Comorbidities in Mexican Mestizo patients with rheumatoid arthritis: A cross-sectional study of 523 patients in a preventive cardio-rheumatology clinic Rosa I. Arvizu-Rivera; Jesus A. Cardenas-de la Garza; Valeria Gonzalez-Gonzalez; Dionicio A. Galarza-Delgado; Jose R. Azpiri-Lopez; Andrea L. Guajardo-Aldaco; Maria F. Elizondo-Benitez; Iris J. Colunga-Pedraza;
Reumatol Clin. 2025;21: